Department of Obstetrics and Gynaecology - Campus Innenstadt, Ludwig-Maximilians-University of Munich, Maistrasse 11, 80337, Munich, Germany.
J Ovarian Res. 2013 Jan 22;6(1):6. doi: 10.1186/1757-2215-6-6.
Anti-Her-2 treatment is successfully administered to Her-2 overexpressing breast cancer patients and significantly implicates upon their survival. Building on these promising results, anti-Her-2 treatment protocols were tested as an option for epithelial ovarian cancer (EOC) as well. However Her-2 signalling is known to be modulated by G-protein coupled receptors (GPCR). Since a common GPCR in ovarian cancer is the FSH receptor (FSHR), we investigated the prognostic significance of Her-2 in patients that had been stratified according to their FSHR status.
A total number of 153 EOC patients were included in this study. Her-2 positivity was assessed using a standard protocol. Intriguingly Her-2 turned out to be an independent prognostic marker for poor overall survival only in those patients that did not express FSHR. This did neither apply for the whole panel nor in case of FSHR co-expression.
We thus conclude that Her-2 can be a negative prognosticator only in FSHR negative EOC cases. Hence by stratifying EOC patients according to their FSHR expression status, we introduce a diagnostic protocol to effectively select EOC patients that would most probably respond to anti-Her-2 treatment. This observation could be of clinical importance in terms of selecting the patient that would most likely benefit from anti-Her-2 treatment.
抗 Her-2 治疗成功用于 Her-2 过表达的乳腺癌患者，显著影响其生存。基于这些有前途的结果，抗 Her-2 治疗方案也被测试作为上皮性卵巢癌（EOC）的一种选择。然而，已知 Her-2 信号受 G 蛋白偶联受体（GPCR）调节。由于卵巢癌中的一种常见 GPCR 是 FSH 受体（FSHR），我们研究了根据 FSHR 状态分层的患者中 Her-2 的预后意义。
本研究共纳入 153 例 EOC 患者。使用标准方案评估 Her-2 阳性。有趣的是，只有在不表达 FSHR 的患者中，Her-2 才是独立的总生存期不良预后标志物。这既不适用于整个面板，也不适用于 FSHR 共表达的情况。
因此，我们得出结论，只有在 FSHR 阴性的 EOC 病例中，Her-2 才能成为阴性预后标志物。因此，通过根据 FSHR 表达状态对 EOC 患者进行分层，我们引入了一种诊断方案，可以有效地选择最有可能对抗 Her-2 治疗有反应的 EOC 患者。这一观察结果在选择最有可能从抗 Her-2 治疗中获益的患者方面可能具有临床重要性。
